Obeticholic acid and the fibroblast growth factor 21 analog pegozafermin led to improvements in liver fibrosis in randomized trials.[6, 7] Single‐molecule agonists with dual or triple activity against the glucagon receptor (GCGR), glucagon‐like peptide‐1 receptor (GLP1R) and glucose‐dependent insulinotropic polypeptide receptor (GIPR) offered potentially greater effects of the reduction of hepatic steatosis and body weight,[8, 9, 10] wherein their action to reduce hepatic lipid accumulation were proved mainly through GCGR signaling.[11, 12, 13]. Here, GCGR is linked to fatty liver disease.